Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019

Matthew J. Jackson, Gregory Vaughan, Fred D. Ledley
doi: https://doi.org/10.1101/2023.06.01.23290833

Article usage

Article usage: June 2023 to December 2024

AbstractFullPdf
Jun 20232481538
Jul 202323217
Aug 202329115
Sep 20231747
Oct 20233265
Nov 202321103
Dec 20232102
Jan 20241406
Feb 2024504
Mar 20242103
Apr 2024727
May 2024303
Jun 20241114
Jul 20241006
Aug 20241503
Sep 20241753
Oct 20241022
Nov 20242015
Dec 20241902
Back to top
Posted June 04, 2023.
Download PDF
Data/Code
Email
Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019
Matthew J. Jackson, Gregory Vaughan, Fred D. Ledley
medRxiv 2023.06.01.23290833; doi: https://doi.org/10.1101/2023.06.01.23290833
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area